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Microbiota associated with type 2 diabetes and its related complications
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bstract
Recently, it has been established that the human resident microbiota plays key roles in health maintenance. Therefore, it has become an
merging prevention and treatment target for metabolic syndrome. The resident microbiota associated with chronic inflammation has been shown
o contribute to the onset of type 2 diabetes mellitus (T2DM). Moreover, the microbiota is altered in the development of T2DM and its comorbid
edical conditions/diseases, including diabetic retinopathy, kidney toxicity, atherosclerosis, hypertension, diabetic foot ulcers, cycstic fibrosis and
lzheimer’s disease. Besides, some anti-T2DM regimens are also based microbiota metabolism-dependent mechanism. This review summarizeshe current knowledge concerning the altered microbiota in the pathogenesis of T2DM and its related complications, which provides novel insights
nto these diseases and the potential intervention strategies from the microbiology point of view.
 2013 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
















The rapid increase of cases of type 2 diabetes mellitus
T2DM) in the past decades has made it a widespread metabolic
isorder. In recent years, an increasing understanding of how
ur microflora is linked to obesity-related T2DM has provided a
ew potential target for reducing the risk of T2DM. The human
ody reservoir harbors trillions of bacteria and the genetic con-
ent of the gut microbiome is 150 times more than that of other
arts of the human body [1]. However, the host–microbe inter-
ctions have not been fully elucidated. The aim of this review is
o expand our view on key roles of microflora during the onset
nd development of T2DM as well as its complications.∗ Corresponding author at: The Key Laboratory of Dairy Biotechnology and
ngineering, Ministry of Education, 306 Zhaowudalu Road, Hohhot 010018,
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i.1.  Gut  microbiota  in  the  pathogensis  of  type  2  diabetes
It is well established that the gut microbiota is involved in
he process of energy harvest accounting for the development
f obesity [2]. Some researches support the view that the gut
icrobiota is essential for the host immunity development [3].
s one of the most concerned obesity-related disorders, T2DM
s associated with abnormal energy metabolism and low-level
hronic inflammation in fat tissues [4,5]. Some hypotheses have
roposed its relation with the presence of gut microbiota.
Principally, the gut microbiota plays an important role in
he progression of prediabetes conditions, such as insulin resis-
ance. Growing evidence in clinical studies suggested that
bese people with insulin resistance were characterized by
n altered composition of gut microbiota, particularly an ele-
ated Firmicutes/Bacteroidetes  ratio compared with healthy
eople [6,7]. Furthermore, transplantation of the obese gut
icrobiota in animals greatly affected the energy harvest of
osts [7]. Consequently, it is proposed that altered micro-
iota in obesity modulates intestinal permeability and increases
etabolic endotoxin secretion that lead to chronic low-level
nflammation, the pathogensis of insulin resistance and onset
f T2DM. [8,9]. Recently, commensal bacterial species, such as
acteroidetes thetaiotaomicron, Akkermansia  muciniphila  and
scherichia coli, were showed to have different influence on thentestinal mucus and glycocalyx layer, which may affect intesti-
al permeability [10]. Besides, microbiota-dependent changes
n gut tight-junction proteins, endocannabinoid system and
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ntestinal alkaline phosphatase activity may be also involved
n altered intestinal permeability and the pathogensis of insulin
esistance [9].
Moreover, the vicious circle between altered microbiota and
he triggered low-level inflammation has also been considered
s a deterioration factor in the development of T2DM. Accu-
ulating evidence has revealed that T2DM patients exhibited
n altered intestinal microbiota which was characterized by
 decrease of Bacteroidetes/Firmicutes  ratio and some func-
ional bacteria (e.g. Biﬁdobacteria) with an increase of various
pportunistic pathogens and some endotoxins-producing Gram-
egative bacteria [11–13]. Firstly, Bacteroidetes/Firmicutes
lteration may modify the host energy metabolism through a
pecific polysaccharide utilization loci mechanism [14]. More-
ver, the accumulation of gut-derived bacterial inflammatory
olecules (e.g. LPS, peptidoglycans and flagellin) in intestine
s thought to accelerate the inflammation in T2DM [15,16].
esides, gastric bypass surgery, an effective way to normalize
he blood glucose level to treat T2DM, could reduce body weight
ue to the alteration of the microbiome at the distal gut [17].
It has been confirmed that some probiotic strains are able
o modulate blood glucose homeostasis, and hence improve
2DM [18]. Several mechanisms have been proposed. Firstly,
robiotic could acted as an effective immune system modulator
gainst altered-microbiota induced chronic inflammation.
t is well-established that obesity induced chronic low-level
nflammation is a leading cause of the progression of T2D
19,20,21]. Some probiotics have been confirmed to prevent
nset of diabetes through down-regulating inflammatory IFN-
nd IL-2 or IL-1  or enhancing anti-inflammatory IL-10
roduction in diabetic animal studies [22–24]. Recently, Lacto-
acillus  reuteri  GMNL-263 have been demonstrated to suppress
erum glucose, insulin, leptin, C-peptide, glycated hemoglobin,
LP-1 level, inflammatory IL-6 and TNF-  in adipose tissues
nd PPAR-  and GLUT4 gene expression in high fructose-fed
ats [25]. Furthermore, human studies have revealed that
robiotic yoghurt consumption could reduce hs-CRP level and
mprove HOMA-IR score in pregnancy which is also considered
s metabolic syndrome [26,27]. In addition, some probiotic
trains show favorable antioxidative effect which is one of the
ffects against chronic inflammation. They are apparently able
o alleviate pancreatic oxidative stress which can lead to chronic
nflammation and apoptosis of pancreatic -cells [28,29].
Moreover, the supplementation of certain probiotic strains
an potentially modulate the lipid metabolism and result in
he reduction of the serum total cholesterol level and LDL-
holesterol, which will reduce the risk of T2DM [30]. Besides,
ndotoxemia has been identified as a triggering factor of insulin
esistance in mice, making the suppression of endotoxemia
y probiotic another potential protective mechanism [9]. An
ral administration of Lactobacillus  casei  Shirota, was able to
nhance the expression of plasma lipopolysaccharide-binding
rotein (LBP) and consequently reduce endotoxemia in murine
odels of obesity and T2DM [31]. In another study, the
onsumption of the probiotic strain, Biﬁdobacterium  animalis
ubsp. lactis  420, suppressed the bacterial translocation pro-
ess from intestine to tissues, which might lead to metabolic
i
iuman Wellness 2 (2013) 167–172
acteremia in the early onset of T2DM [32]. From the perspec-
ive of nutrition, a novel probiotic strain, L.  casei  Zhang, was
ecently proven to exhibit osteocalcin-elevating effect leading to
mprovement of oral glucose tolerance in impaired glucose toler-
nce (IGT) rats. This was probably achieved via gut Bacteroides
ragilis enriched vitamin K2 mechanism [33].
.  Microbiota  and  T2DM  complications
.1.  Diabetic  retinopathy
Diabetic retinopathy accounts for more than 60% incidence
n T2DM [34]. As expected, a higher frequency of Gram-positive
acteria and a higher proportion of coagulase negative staphylo-
occi was detected in diabetic patients, especially those with
etinopathy [35,36]. This result was supported by Bilen et al.,
ho found that Staphylococcus  epidermidis  and Staphylococ-
us aureus  were the predominant conjunctival organisms in
2DM patients, and the frequency of S. aureus  isolated from
he patients’ eyes were higher than that of T1DM and healthy
ubjects [37]. Parkinson’s disease is also one of complications
ith chronic diabetic neuropathy in T2DM [38]. Kusbeci et al.
bserved that the occurence of S.  aureus  was significantly higher
n the conjunctival flora of Parkinson’s patients than in healthy
ontrols [39].
.2.  Renal  toxicity  and  kidney  stones
A high proportion of T2DM patients also suffer from clinical
ondition of chronic kidney toxicity, such as kidney stones. This
s probably due to the disruption of colonic epithelial perme-
bility which was implicated in the pathogenesis of T2DM and
hronic kidney toxicity [40]. By phylogenetic microarray analy-
is, chronic kidney disease patients showed significant changes
n 190 microbial operational taxonomic units (OTUs), particu-
arly the high abundance of the Enterobacteriaceae  compared
o the healthy control group [40].
Moreover, Zheng et al. recently demonstrated that the biocon-
ersion of melamine by gut microbiota, particularly Klebsiella,
as essential for renal toxicity and the formation of crystal
tones [41]. Oxalobacter  formigenes, a commensal gut microbe,
as been shown to improve the clinical condition of kidney stone
atients [42]. However, commonly available probiotics, includ-
ng Lactobacillus  and Biﬁdobacterium  species, were insufficient
n degrading oxalate to treat kidney stones [43,44]. Besides, the
xtent of calcium oxalate stone formation may be dependent on
he microbiota. This is evidenced by the low expression level
f vitamin K epoxide reductase complex subunit 1 (VKORC1)
n patients with calcium oxalate urolithiasis. The expression of
KORC1 could be influenced by vitamin K2 producing gut
acteria [45,46].
.3.  HypertensionHypertension and T2DM are closely related to each other
n clinical setting. Apart from being a complication to T2DM,
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ymptom of metabolic syndrome. Recent evidence suggests that
etabolic syndrome is partially regulated by the gut micro-
iota [6]. However, only very little is known about the role
f the host gut microbiota in the case of hypertension. One
xperimental finding supporting the hypothesis of blood pres-
ure regulation by the gut microbiota was provided by Pluznick
t al. using a mouse model. Propionate is one of the end-
roducts derived from the gut microbiota. It was revealed
hat, in response to propionate, the expression of renal olfac-
ory receptor 78 (Olfr78) was increased, in turn mediating
he secretion of rennin [47]. Consequently, the blood pres-
ure was elevated. On the contrary, G protein-coupled receptor
GPR41), a short-chain fatty acid receptor, negatively regu-
ated the blood pressure. Hence, it was concluded that these gut
icrobiota-derived short-chain fatty acids, in particular propi-
nate, participated in the blood pressure regulation process via
oth receptors.
Furthermore, it has been reported that Lactobacillus  john-
onii La1 ingestion could not only maintained low blood
lucose level in streptozotocin (STZ)-induced diabetic rats,
ut also prevent rats from elevated blood pressure by reduc-
ng the renal sympathetic nerve activity and enhancing the
arasympathetic nerve activity through the sympathoadrenal
xis [48,49].
.4.  Atherosclerosis
Most T2DM patients tend to have higher levels of serum
ipids, which predisposes them to atherosclerosis. Associations
etween microbiota and atherosclerosis have been proposed.
oren et al. analyzed the oral, gut and atherosclerotic plaque
icrobiota in atherosclerotic patients [50]. Good correlation was
ound between total abundances of Veillonella  and Streptococcus
n the oral cavity and the atherosclerotic plaque. Moreover, sev-
ral oral and intestinal bacterial taxa, including Streptococcus,
eisseria and Fusobacterium, are correlated with the plasma
holesterol levels.
It is well established that probiotics with bile salt hydrolase
ctivity could accelerate the bioconversion of cholesterol to pri-
ary bile, showing acids a serum lipids-reducing effect [30].
oroti et al. reported that the administration of a synbiotic bev-
rage called shake, which contained Lactobacillus  acidophilus,
iﬁdobacterium biﬁdum  and oligofructose, markedly increased
he plasma HDL cholesterol and decreased the condition of
asting glycemia in elderly T2DM patients [51].
.5.  Cystic  ﬁbrosis
Patients with cystic fibrosis (CF) are also associated with
igh incidence of T2DM [52]. There is increasing evidence that
n altered microbiota in CF respiratory tract plays an important
ole in its pathogenesis. The most commonly isolated bacterial
pecies in airways of CF patients were Haemophilus  inﬂuenzae,
. aureus, Pseudomonas  aeruginosa  and Burkholderia  cepacia
omplex species [53]. Nowadays, high-throughput sequencing
ethods, such as 16S amplicon pyrosequencing, were applied
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oddard et al. found that CF lungs were typically dominated by
nly one to three species by direct sampling of explanted lungs
54]. They also observed that the microflora in the sputum and
hroat specimens could not represent the typical CF microflora.
A recent study monitoring the development of gut and
espiratory microbiomes in CF infancy revealed that both com-
artments shared some common core microbes and the temporal
uctuation of microbiota over time was in concordance with
ach other. Moreover, a change in diet resulted in the alter-
tion in the airway microbiota composition [55]. These together
uggest that diet, gut microflora and the development of the
espiratory tract microbiota are linked with one another. Because
f this link, it is logical to hypothesize that the oral adminis-
ration of probiotics may reduce symptoms caused by CF. At
east two individual studies confirmed the probiotic effects of
actobacillus  GG in alleviating the intestinal inflammation and
ulmonary exacerbations rate in CF patients [56,57]. Another
ommon symptom of CF children is the malabsorption of bile
cids. Roy et al. showed that antibiotic treatment reversed this
ondition, which was due to the reduction of gut anaerobes
nd their related enzymatic activities, such as bile salt hydro-
ase (BSH) [58]. Gut bile salt hydrolases deconjugate glycine or
aurine from bile salts. The deconjugated bile salts are more effi-
ient in lipid emulsification and absorption in the gut. Hence, the
pplication of BSH-bearing probiotics may be another potential
reatment for CF patients.
.6.  Diabetic  foot  ulcers
Diabetic foot ulcers leading to infection and limb loss are both
inked to an increasing risk of age-related diabetes. Several well-
xplored microorganisms, including Staphylococcus  species, P.
eruginosa and E.  coli, etc., were isolated from patients with
nfected diabetic foot ulcers [59]. The main plantar foot normal
ora are coagulase-negative Staphylococcus  species, which are
ecognized as strong competitors for the infection-associated
. aureus. Recently, Redel et al. found that the ratio of non-
athogenic Staphylococcus  to pathogenic S.  aureus  on the feet of
iabetic men was lower, compared to the normal subjects [60].
y bacterial 16S rRNA gene pyrosequencing, Gardner et al.
nalyzed the microbiomes in diabetic foot ulcers and revealed
hat the ulcer depth and duration were negatively correlated with
he abundance of Staphylococcus, whereas the ulcer duration
as positively correlated with that of Proteobacteria  [61].
.7.  Alzheimer’s  disease
T2DM may result in an increase in risk in Alzheimer’s
isease (AD) and these may share common pathogenic mecha-
isms [62,63]. Vignini et al. summarized the recent experimental
vidence and potential mechanisms that link the two medical
onditions, including the possible roles of insulin deficiency
r insulin resistance in facilitating cerebral -amyloidogenesis,
hich accounts for the increased risk of diabetes patients to
ementia [64]. In addition, AD had even been considered as the
ype 3 diabetes [65].
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Currently, little data is available on the resident microflora
f AD patients, thus how they are related to each other remains
oorly understood. To date, only one study has directly com-
ared the gut physiology and microbiota structure between wild
ype and AD transgenic mice. The gut alteration in AD trans-
enic mice was characterized by an increase of Gram-negative
acteria accompanied by mucosal disruption [66]. Moreover, the
myloid precursor protein (APP) expression level was signifi-
antly upregulated in the intestine of AD, but not in the control
ice.
Even though the research area of the gut microbiota in AD is
nderstudied, the possibility of preventing from or treating AD
ia enteria bacteria has been considered. Indole propionic acids
IPAs) are putative drugs for treating AD and T2DM [67,68].
he plasma amino acid metabolites, including the bioactive
ndole-containing metabolites, of germ-free mice were signif-
cantly affected as compared to the normal mice. Moreover, the
ioconversion of indole to indole-3-propionic acid was found
o be solely dependent on the gut microbiota [69]. Therefore,
anipulations of gut microbiota seem to be a key to restore the
lasma IPA level. Another metabolic characteristic of AD was
he loss of GABA(A) receptors in the hippocampus of the brain
70]. The probiotic strain L.  rhamnosus  JB-1, an effective mod-
lator of the gut microbiota, was proved to be able to increase
ABA(A2) in the hippocampus of mice [71]. These are direct
vidence showing the interaction between the residence flora and
he host metabolism, which offers novel potential prophylaxis
r treatment targets for AD.
.  Anti-T2D  regimens  concerning  microbiota
In recent years, due to side-effects of anti-T2D drugs for
lucose or insulin resistance control (e.g. metformin and piogli-
azone) and anti-inflammatory drugs for T2D complications (e.g.
SAIDs), natural anti-T2D compounds extracted from plants
otentially with less side effects have drawn more attention
4,72]. Particularly, these drugs with GI and cardiovascular side
ffects brought high risks for long-term use [73]. Berberine,
 component from traditional Chinese herb Coptis  chinensis,
as been recently demonstrated to have anti-diabetic effect
hrough modulating microbiota composition since it is mainly
bsorbed by gut [74]. The major bioactive constituents of Gins-
ng, another important anti-diabetic Chinese herb, were mainly
rom microbiota-mediated metabolism of ginsenosides [75].
nhibition of intestinal α-glucosidase is another strategy to con-
rol the increase in blood glucose at early onset of T2D [76].
owever, drugs for this target may lead to GI side effects [77].
 great deal of polyphenols, a series of natural compounds from
ea, coffee, wine, fruit, vegetables, and chocolate, can inhibit
lucose metabolism enzymes to exert anti-diabetic effect with
o side effect [78,79]. Typically, wine polyphenols have been
onfirmed to significantly modulate some taxa of gut microbiota
nd reduce serum lipids and inflammatory C-reactive protein in
umans [80]. Moreover, the microbiota is also important for the
etabolism of polyphenols (e.g. catechin and gallocatechin from
[uman Wellness 2 (2013) 167–172
reen tea) promoting their bioavailability in the small intestine
81].
.  Conclusion
In summary, great progress has been made in the field of the
esident microbiota in T2DM in recent years. Microbiota con-
ributes not only to low-level inflammation in the onset of T2D,
ut also to the further development of T2D through inflammatory
omponents. It has also been extended to various T2DM related
omplications, including diabetic retinopathy, kidney toxicity,
therosclerosis, hypertension, diabetic foot ulcers, cycstic fibro-
is and Alzheimer’s disease. These studies together support the
rucial role of microbiota in maintaining the intestinal barrier
ntegrity, sustaining a normal metabolic homeostasis, protecting
he host from infection by pathogens, enhancing host defense
ystem and even influencing the nervous system in T2DM.
icrobiota-mediated mechanism is also involved in some anti-
2D regimens using natural compounds from plants. However,
he potential mechanisms linking the microbiota to T2DM have
ot been fully elucidated and continuing research efforts are
eeded.
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